KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) Research & Development (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Research & Development for 17 consecutive years, with $70.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 11.68% to $70.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $275.6 million, a 6.86% decrease, with the full-year FY2025 number at $275.6 million, down 6.86% from a year prior.
  • Research & Development was $70.3 million for Q4 2025 at Bio-Rad Laboratories, down from $71.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $91.0 million in Q3 2024 to a low of $43.5 million in Q3 2023.
  • A 5-year average of $67.0 million and a median of $65.6 million in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: tumbled 37.76% in 2023, then surged 109.02% in 2024.
  • Bio-Rad Laboratories' Research & Development stood at $58.9 million in 2021, then increased by 12.5% to $66.2 million in 2022, then decreased by 3.53% to $63.9 million in 2023, then increased by 24.62% to $79.6 million in 2024, then fell by 11.68% to $70.3 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Research & Development are $70.3 million (Q4 2025), $71.3 million (Q3 2025), and $60.5 million (Q2 2025).